Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus radiotherapy for bladder preservation in invasive bladder cancer
jRCT2031180060Phase 2Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in bladder cancer and transitional cell carcinoma of the bladder (TCC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Started Jan 2019; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
bladder cancertransitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on jRCT2031180060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031180060.